These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1260770)

  • 1. Experimental studies at Southern Research Institute with DTIC (NSC-45388).
    Montgomery JA
    Cancer Treat Rep; 1976 Feb; 60(2):125-34. PubMed ID: 1260770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of DTIC (NSC-45388) in animals.
    Venditti JM
    Cancer Treat Rep; 1976 Feb; 60(2):135-40. PubMed ID: 1260771
    [No Abstract]   [Full Text] [Related]  

  • 3. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
    Gottlieb JA; Benjamin RS; Baker LH; O'Bryan RM; Sinkovics JG; Hoogstraten B; Quagliana JM; Rivkin SE; Bodey GP; Rodriguez V; Blumenschein GR; Saiki JH; Coltman C; Burgess MA; Sullivan P; Thigpen T; Bottomley R; Balcerzak S; Moon TE
    Cancer Treat Rep; 1976 Feb; 60(2):199-203. PubMed ID: 769974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats.
    Beal DD; Skibba JL; Croft WA; Cohen SM; Bryan GT
    J Natl Cancer Inst; 1975 Apr; 54(4):951-7. PubMed ID: 1127724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
    Metelmann HR; Von Hoff DD
    Int J Cell Cloning; 1983 Apr; 1(1):24-32. PubMed ID: 6674387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies with DTIC (NSC-45388) in various malignancies.
    Slavik M
    Cancer Treat Rep; 1976 Feb; 60(2):213-4. PubMed ID: 769976
    [No Abstract]   [Full Text] [Related]  

  • 9. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the mechanism of action of DTIC (NSC-45388).
    Bono VH
    Cancer Treat Rep; 1976 Feb; 60(2):141-8. PubMed ID: 944096
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
    Rose WC; Schurig JE; Huftalen JB; Bradner WT
    Cancer Res; 1983 Apr; 43(4):1504-10. PubMed ID: 6831399
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells.
    Beal DD; Skibba JL; Whitnable KK; Bryan GT
    Cancer Res; 1976 Aug; 36(8):2827-31. PubMed ID: 179708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of combination adriamycin (NSC-123127) and DTIC (NSC-45388) in children with advanced stage IV neuroblastoma.
    Leikin S; Bernstein I; Evans A; Finklestein J; Hittle R; Klemperer M
    Cancer Chemother Rep; 1975; 59(5):1015-8. PubMed ID: 1106842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
    Testorelli C; Archetti YL; Aresca P; Del Vecchio L
    Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinogenicity of cytostatic triazenes.
    Kolar GF
    IARC Sci Publ; 1986; (78):111-26. PubMed ID: 3583385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-phenylimidazole (NSC-166721) and 4-carbethoxy-5-(3,3-dimethyl-1-triazeno)-2-methylimidazole (NSC-166722) as potential antitumor agents.
    Heyes J; Catherall EJ; Cockburn A
    Cancer Chemother Rep; 1973; 57(3):263-8. PubMed ID: 4751253
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanism of action and pharmacology studies with DTIC (NSC-45388).
    Loo TL; Housholder GE; Gerulath AH; Saunders PH; Farquhar D
    Cancer Treat Rep; 1976 Feb; 60(2):149-52. PubMed ID: 1260772
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity.
    Fioretti MC; Bianchi R; Romani L; Bonmassar E
    J Natl Cancer Inst; 1983 Dec; 71(6):1247-51. PubMed ID: 6581361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.